| Literature DB >> 32647734 |
Jacqueline E Baron1, Emily A Parker1, Kyle R Duchman1, Robert W Westermann1.
Abstract
BACKGROUND: Quadriceps dysfunction after anterior cruciate ligament (ACL) reconstruction is common and may affect return to sport due to resulting muscle atrophy and muscle weakness.Entities:
Keywords: ACL; anterior cruciate ligament reconstruction; blood flow restriction; nerve block; quadriceps; tourniquet
Year: 2020 PMID: 32647734 PMCID: PMC7328065 DOI: 10.1177/2325967120930296
Source DB: PubMed Journal: Orthop J Sports Med ISSN: 2325-9671
Inclusion and Exclusion Criteria for Studies Assessing Postoperative Quadriceps Atrophy and Strength After Anterior Cruciate Ligament (ACL) Reconstruction
| Inclusion | Exclusion |
|---|---|
| Human studies | Non-English language |
Figure 1.PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram of included and excluded studies examining postoperative quadriceps atrophy and strength following anterior cruciate ligament reconstruction.
Coleman Methodology Score
| Part A |
| 1. Study size (10) |
| 2. Mean duration of follow-up (5) |
| 3. Number of surgical procedures (10) |
| 4. Type of study (15) |
| 5. Diagnostic certainty (5) |
| 6. Description of surgical procedure (5) |
| 7. Description of postoperative rehabilitation (10) |
| Part B |
| 1. Outcome measures (10) |
| 2. Outcome assessment (15) |
| 3. Selection process (15) |
| Total possible = 100 points |
Consensus Modified Coleman Methodology Score (MCMS) of Evidence Quality by Study
| Blood Flow Restriction | Supplement | Tourniquet | Nerve Block | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takarada[ | Iverson[ | Ohta[ | Tyler[ | Laboute[ | Barker[ | Kokki[ | Appell[ | Nicholas[ | Faggal[ | Arciero[ | Abdallah[ | Magnussen[ | Okoroha[ | Runner[ | |
|
| |||||||||||||||
| Study size—No. of patients | 0 | 0 | 4 | 4 | 4 | 0 | 0 | 0 | 4 | 4 | 4 | 7 | 0 | 4 | 7 |
| Mean follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Percentage of patients with follow-up | 5 | 5 | 5 | 3 | 5 | 5 | 5 | 0 | 5 | 5 | 5 | 5 | 5 | 5 | 0 |
| No. of interventions per group | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Type of study | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 10 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
| Diagnostic certainty | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Description of surgical technique | 3 | 3 | 3 | 5 | 3 | 3 | 3 | 3 | 5 | 3 | 5 | 3 | 3 | 3 | 3 |
| Description of postoperative rehabilitation | 0 | 5 | 5 | 3 | 5 | 5 | 0 | 0 | 0 | 5 | 5 | 0 | 0 | 5 | 0 |
|
| |||||||||||||||
| 1. Outcome criteria | |||||||||||||||
| Outcome measures clearly defined | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Timing of outcome assessment clear | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Use of outcome criteria with reported good reliability | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Use of outcome with good sensitivity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2. Procedure for reporting outcomes | |||||||||||||||
| Patients recruited | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Independent investigator | 0 | 2 | 0 | 0 | 2 | 0 | 2 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 0 |
| Written assessment | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Patient-centered data collected | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| 3. Description of patient selection process | |||||||||||||||
| Selection criteria reported and unbiased | 0 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Recruitment rate reported and ≥80% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Eligible patients not included in the study satisfactorily accounted for | 0 | 0 | 5 | 5 | 0 | 0 | 0 | 0 | 5 | 0 | 5 | 5 | 5 | 5 | 0 |
|
| 48 | 60 | 67 | 65 | 64 | 58 | 55 | 43 | 66 | 64 | 71 | 67 | 60 | 69 | 55 |
Median score, 64; range, 43-71.
Demographics of Study Participants Undergoing ACL Reconstruction With Perioperative and Postoperative Interventions
| Intervention and Study Author (Year) | No. of Patients (Male, Female) | No. of Participants, Experimental, Control | Age, y, Median (Range) or Mean ± SD | BMI, kg/m2 or [Weight, kg]; Experimental, Control | Total No. of Patients (% Male) | Total No. of Participants, Experimental, Control | Overall Age, y, Mean ± SD | Overall BMI, kg/m2 or [Weight, kg]; Mean ± SD |
|---|---|---|---|---|---|---|---|---|
| Perioperative femoral nerve block | 247 (53.8) | 120, 127 | 26.3 ± 4.2 | 82.0 ± 1.0 | ||||
| Abdallah[ | 100 (64, 36) | 48, 52 | 32.4 (28.9-35.9) | 81.3, 79.4 | ||||
| Intraoperative tourniquet use | 196 (76.0) | 102, 94 | 28.0 ± 4.4 | 72.2 ± 2.2 | ||||
| Kokki[ | 31 (22, 9) | 13, 18 | 31 (16-48) | 72, 75 | ||||
| Postoperative supplement use | 125 (68.0) | 62, 63 | 28.5 ± 4.6 | 70.7 | ||||
| Tyler[ | 60 (33, 27) | 30, 30 | 30.4 | 70.7 | ||||
| Postoperative blood flow restriction training | 84 (55.6) | 42, 42 | 27.3 ± 3.3 | 67.2 ± 8.0 | ||||
| Takarada[ | 16 (8, 8) | 8, 8 | 22.7 | 58.8, 62.2 | ||||
| Median (range) | 160.5 (84-247) | 82 (42-120) | 27.7 (26.3-28.5) | 71.5 (67.2-82.0) | ||||
ACL, anterior cruciate ligament; BMI, body mass index.
All nerve block studies compared patients who had femoral nerve blocks versus patients with no nerve blocks or adductor canal blocks; femoral nerve blocks are considered the experimental group for this analysis.
Significant Changes in Postoperative Quadriceps Measures After ACL Reconstruction Stratified by Intervention Type; Pooled Quadriceps Measures per Intervention Type
| Total Patients (Experimental, Control) | Follow-up, Median (Range) | Pooled Quadriceps Outcomes per Intervention | Significant Postoperative Quadriceps Changes, Studies/Patients (% Experimental Group) |
|---|---|---|---|
| Perioperative femoral nerve block | |||
| 247 (120, 127) | 5.6 mo (0.2-10.3 mo) | Strength (–) | 2 studies/62 patients (51.7%) |
| Intraoperative tourniquet use (5 studies) | |||
| 196 (102, 94) | 6.8 wk (1 d to 6 mo) | EMG values (–) | 1 study/31 patients (60.8%) |
| Muscle structure (–) | 1 study/14 patients (100%) | ||
| Leg circumference (–) | 2 studies/55 patients (73.3%) | ||
| Postoperative supplement use (3 studies) | |||
| 125 (62, 63) | 3.3 mo (3 wk to 6 mo) | Leg circumference (+) | 1 study/22 patients (68.8%) |
| Postoperative blood flow restriction training (3 studies) | |||
| 84 (42, 42) | 6.8 wk (2-16 wk) | Extensor cross-sectional area (+) | 3 studies/30 patients (71.4%) |
| Strength (+) | 1 study/22 patients (100%) | ||
ACL, anterior cruciate ligament; EMG, electromyography.
A minus symbol indicates that the outcome was associated with decreases in quadriceps measurements postoperatively. A plus symbol indicates that the outcome was associated with increases in quadriceps measurements postoperatively.
All nerve block studies compared patients who had femoral nerve blocks versus patients with no nerve blocks or adductor canal blocks; femoral nerve block denoted experimental group.
Postoperative Quadriceps Volume and Strength After ACLR Stratified by Intervention Type
| Study Author (Year) | Primary or Revision ACLR | Target Intervention | ACLR Graft Type | Outcome Measure | Follow-up Period After ACLR | Difference in Results |
|---|---|---|---|---|---|---|
| Perioperative femoral nerve block | ||||||
| Abdallah[ | Primary | Perioperative FNB vs ACB | BTB, n = 29 | 24-hour analgesic consumption, VAS scores, MVIC | 1 day | FNB group had significantly lower MVIC and a significantly larger percentage reduction at 45 minutes after block; no patients reported persistent weakness at 1 week. |
| Magnussen[ | Not indicated | Perioperative FNB vs no nerve block | STG all patients | KOOS, isokinetic quadriceps strength testing | 6 months | KOOS and quadriceps strength (limb symmetry) were lower for the FNB group at 6 weeks only. |
| Okoroha[ | Primary | Perioperative FNB vs liposomal bupivacaine | BTB, n = 31 | Isokinetic quadriceps strength, functional testing | 9 months | No significant differences were seen between the block and control groups; 13% of the FNB patients had persistent motor/sensory complications at follow-up. |
| Runner[ | Primary | Perioperative FNB vs ACB | QTB, n = 58 | Analgesic consumption, time to straight-leg raise, isokinetic strength testing | 6 months | No significant differences were seen between the FNB and ACB groups for any measures. |
| Intraoperative tourniquet use | ||||||
| Kokki[ | Not indicated | 250 mm Hg vs 350 mm Hg tourniquet during ACLR | BTB all patients | Peroneal nerve MCV and SCV; EMG of vastus medialis | 3 weeks | No significant difference was observed between groups; both groups had significant, detrimental EMG/NCS changes postoperatively. |
| Appell[ | Not indicated | 400 mm Hg tourniquet during ACLR | STG all patients | Alterations in muscle structure of vastus lateralis biopsies | 1 day | Identifiable muscle damage was present at 15 minutes after tourniquet inflation and continued to worsen during surgery. |
| Nicholas[ | Primary | Tourniquet (300 mm Hg) vs no tourniquet during ACLR | BTB all patients | Thigh and calf circumference, isometric plantarflexion and dorsiflexion strength | 6 months | Significantly greater decrease in thigh girth occurred in the tourniquet group. |
| Faggal[ | Primary | Tourniquet (350 mm Hg) vs no tourniquet during ACLR | STG all patients | Pain; hemarthrosis; drainage; isokinetic hamstring and quadriceps strength; thigh and calf circumference | 6 months | Experimental group had significantly greater drainage, hemarthrosis, early pain, and smaller calf and thigh girth at 2 weeks. |
| Arciero[ | Primary | Tourniquet (269 mm Hg) vs no tourniquet for ACLR | BTB all patients | Thigh and calf girth, EMG, creatine phosphate levels, arthrometry, single-leg hop, Lysholm knee score, quadriceps and hamstring isokinetic testing | 1 year | No significant differences were noted. |
| Postoperative supplement use | ||||||
| Tyler[ | Not indicated | Creatine supplements after ACLR | BTB all patients | Isokinetic strength of quadriceps, hamstring, hip flexor, abductors, and adductors; isokinetic power of quadriceps, hamstring | 6 months | No significant differences were observed. |
| Laboute[ | Not indicated | Leucine supplements during 2- to 3-week period 200 days after ACLR | STG, n = 39 | Thigh perimeter, flexor and extensor isokinetic strength, single-leg testing, body fat percentage | 2-3 weeks (all patients 6-7 months after ACLR) | Experimental group had significantly larger thigh circumference 10 cm proximal to the patella. |
| Barker[ | Not indicated | Vitamin E and C supplements preoperatively until after ACLR | STG, n = 19 | Antioxidant levels, thigh circumference, muscle fiber circumference, muscle cytokine levels, single-leg power, single-leg isometric force | 3 months | Experimental group had no significant difference in outcome measures; patients with higher baseline vitamin C levels had significant positive correlation with muscle strength recovery. |
| Postoperative blood flow restriction training | ||||||
| Takarada[ | Not indicated | Blood flow restriction after ACLR | Not indicated | Knee extensor and flexor CSA on MRI | 2 weeks | Significantly less extensor CSA loss was observed in experimental group at POD 14. |
| Iverson[ | Primary | Blood flow restriction during exercises after ACLR | STG all patients | Quadriceps CSA on MRI | 2 weeks | No significant difference was observed at POD 14. |
| Ohta[ | Not indicated | Blood flow restriction during exercises after ACLR | STG all patients | Knee extensor and flexor torque; extensor, flexor, and adductor CSA on MRI; muscle fiber diameter | 4 months | Experimental group had significant increase in strength, larger extensor CSA. |
ACB, adductor canal block; ACLR, anterior cruciate ligament reconstruction; BTB, bone-tendon-bone graft; CSA, cross-sectional area; EMG, electromyography; FNB, femoral nerve block; KOOS, Knee injury and Osteoarthritis Outcome Score; MCV, motor conduction velocity; MRI, magnetic resonance imaging; MVIC, maximal voluntary isometric quadriceps contraction; NCS, nerve conduction study; POD, postoperative day; QTA, quadriceps tendon allograft; QTB, quadriceps tendon autograft; SCV, sensory conduction velocity; STG, semitendinosus and gracilis graft (hamstring graft); TAA, tibialis anterior allograft; VAS, visual analog scale.